Mindful Awareness Program for the Prevention of Dementia: A Randomized Controlled Trial (MAPRCT)
Primary Purpose
Dementia
Status
Completed
Phase
Not Applicable
Locations
Singapore
Study Type
Interventional
Intervention
Mindful Awareness Program
Health Education Program
Sponsored by
About this trial
This is an interventional prevention trial for Dementia focused on measuring Prevention of dementia, Mindful awareness program, Mild cognitive impairment, Mindfulness, Elderly, Cognitive decline
Eligibility Criteria
Inclusion Criteria:
an elderly person between the age of 60 and 85 living in the community and fulfill the operational criteria/definition of MCI:
- At least one age-education adjusted neuropsychological test Z score < -1.5
- Do not meet DSM-IV criteria for dementia syndrome
- Memory / Cognitive complaint, preferably corroborated by a reliable informant
- Intact Activities of Daily Living.
- function independently
- do not suffer from dementia,
- able to travel on their own to the data collection site and participate in the MAP or HEP
Exclusion Criteria:
- Those who do not meet the above inclusion criteria (ie. Do not have a MCI diagnosis),
- Those with Dementia or Normal Ageing
- Have a neurological condition (e.g., epilepsy, Parkinson's Disease),
- Have a major psychiatric condition (e.g., major depressive disorder)
- Suffer from a terminal illness (e.g., cancer).
- Have significant visual or hearing impairment, or
- Marked upper and lower limb motor difficulties, which may affect their ability to participate in the study.
- Are in another interventional study at the same time
Sites / Locations
- Training and Research Academy
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Mindful Awareness Program
Health Education Program
Arm Description
18 sessions of mindful awareness program teaching the elderly mindful awareness practice techniques
18 sessions of health education program focusing on healthy living topics
Outcomes
Primary Outcome Measures
Change from baseline Mini-Mental State Examination (MMSE) at 3 months and 9 months
Mini-Mental State Examination (MMSE) is a brief 30-point questionnaire administered by health care professionals to screen for cognitive impairment. The score ranges from 0 to 30; the higher the score, the less impaired is the participant's cognitive function.
Change from baseline Clinical Dementia Rating (CDR ) at 3 months and 9 months
Clinical Dementia Rating (CDR ) is a 5-point scale used to characterize six domains of cognitive and functional performance applicable to Alzheimer disease and related dementias: Memory, Orientation, Judgment & Problem Solving, Community Affairs, Home & Hobbies, and Personal Care.
Change from baseline Rey Auditory Verbal Learning Test (RAVLT) at 3 months and 9 months
Rey Auditory Verbal Learning Test (RAVLT) evaluates declarative verbal learning and memory.
Change from baseline Digit Span Task at 3 months and 9 months
Digit Span Task, which consists of a Digit Span Forward (DSF) and a Digit Span Backward (DSB) task is used to assess attention and verbal working memory.
Change from baseline Colour Trails Tests (CTT) at 3 months and 9 months
Colour Trails Tests (CTT) 1 and 2 assesses sustained attention and sequencing.
Change from baseline Block Design at 3 months and 9 months
Block Design is a subtest that is administered as part of several of the Wechsler Intelligence tests, and it primarily measures visual-spatial and organizational processing abilities, as well as non-verbal problem-solving skills.
Change from baseline Semantic Verbal Fluency (Animals) at 3 months and 9 months
Semantic Verbal Fluency (Animals) taps lexical knowledge and semantic memory organization.
Change from baseline fMRI scan at 3 months
Functional Magnetic Resonance Imaging (fMRI) will be employed to examine changes in functional connectivity. Images will be acquired on a 3T Siemens scanner using a standard Siemens whole head coil. All subjects will undergo the task-free fMRI scan after being instructed only to remain awake with their eyes closed. White Matter Diffiusion Tractography Imaging (DTI) will be utilized to identify anatomical connections between functionally correlated regions . The MRI Brain Scan is non-invasive and does not involve the use of Contrast; duration of each scan is approximately one hour.
Change from baseline Biomarkers: blood sample at 3 months and 9 months
5 ml of blood will be collected using plasma tubes with indomethacin (15uM final conc) and BHT (20ul of 2mM) will be added prior to freezing (-80 Degree Celsius) to preserve the sample and prevent artifacts (at baseline, 3 months, 9 months).
3 ml of blood will be collected using tubes with no coagulant (at baseline, 3 months and 9 months).
5 ml of blood will be collected using Tempus Blood RNA tubes and will be stored in a refrigerator at approximately 4 Degree Celsius (at baseline and 9 months).
Blood sample would be analysed for cytokine levels; chromosomal studies and terminal telomere restriction fragment length.
Change from baseline Biomarkers: urine sample at 9 months
15 ml sample of urine will be collected and frozen as quickly as possible. Urine sample would be analysed for oxidative biomarkers.
Change from baseline Biomarker - fecal sample at 3 months and 9 months
A fecal sample will also be collected in a tube with RNALater and microbeads. These can be kept at 40C till processing. Fecal sample would be analysed for bacteria.
Change from baseline Biomarker - saliva sample at 3 months and 9 months
Saliva will be collected in a test-tube by having participants continuously spit into a 50ml centrifuge tube for 5 minutes. Saliva sample would be analysed for salivary cortisol analysis, DNA extraction and sequencing for stress biomarkers (cytokines).
Secondary Outcome Measures
Change from baseline Basic Health Screen at 3 months and 9 months
the Blood pressure, Pulse rate, Height and Weight will be measured.
Change from baseline Activities of daily Living (ADL) at 3 months and 9 months
Activities of daily Living (ADL) is a questionnaire to screen for functional assessment.
Change from baseline Instrumental Activities of Daily Living (IADL) at 3 months and 9 months
Instrumental Activities of Daily Living (IADL) is a questionnaire to screen for functional assessment.
Change from baseline Geriatric Depression Scale (GDS) at 3 months and 9 months
Psychological well-being will be assessed using the Geriatric Depression Scale. Subjects with high scores will not be enrolled into the study and will be informed of the scores and advised to see a doctor at a polyclinic or their family physician with a referral letter prepared for this purpose.
Change from baseline Geriatric Anxiety Inventory (GAI) at 3 months and 9 months
Psychological well-being will be assessed using the Geriatric Anxiety Inventory (GAI). Subjects with high scores will not be enrolled into the study and will be informed of the scores and advised to see a doctor at a polyclinic or their family physician with a referral letter prepared for this purpose.
Full Information
NCT ID
NCT02286791
First Posted
November 3, 2014
Last Updated
August 16, 2015
Sponsor
National University of Singapore
1. Study Identification
Unique Protocol Identification Number
NCT02286791
Brief Title
Mindful Awareness Program for the Prevention of Dementia: A Randomized Controlled Trial
Acronym
MAPRCT
Official Title
Mindful Awareness Program for the Prevention of Dementia: A Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
August 2015
Overall Recruitment Status
Completed
Study Start Date
September 2014 (undefined)
Primary Completion Date
June 2015 (Actual)
Study Completion Date
June 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
National University of Singapore
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The objective of this study is to determine whether regular Mindful Awareness Program (MAP) may reverse cognitive impairment and/or prevent further cognitive decline among older adults. 60 elderly with mild cognitive impairment (MCI) were randomized to participate in either the MAP or the Health Education Program (HEP). Sessions will be conducted weekly for 12 weeks, and monthly for 6 months. Participants would be assessed at 3 time-points: at the start, at 3-months and at 9-months.
It was hypothesized that as compared to HEP participants, MAP participants will (1) have improved functional connectivity, (2) have a decreased risk in cognitive decline and (3) report higher psychological well-being.
Detailed Description
Participants Study participants are community-dwelling elderly.
Assessments Demographic data will be collected at the start. Psychological tests for depression and anxiety and neuropsychological tests of cognitive functioning will be done at the start, at 3-months and at 9-months, the end of the study. A urine sample will be collected at the start and at the end of the study; blood, fecal and saliva samples will be collected at all three time points. Participants will also undergo a brain neuro-imaging scan at the start of the study and at the 3-months interval.
Intervention Sessions This is an intervention study with a control group design. The strength of this design is its experimental nature with randomization. The control group is the health education program participants.
In the Mindful Awareness Program, all 30 participants will be seen in a group format once a week for 40 minutes for 12 weeks, followed by once a month for 40 minutes for 6 months. The intervention is modelled on similar groups teaching mindfulness meditation to the elderly. The sessions will be led by an experienced instructor who has conducted pilot studies on the use of mindful awareness practice techniques with the elderly.
Participants shall be required to practice these techniques at home daily and will be asked to keep a log of their practice.
For the Health Education Program, all 30 participants will be seen in a group format once a week for 40 minutes for 12 weeks, followed by once a month for 40 minutes for 6 months. Each weekly session will cover a healthy living topic related to maintaining and improving cognitive function. The monthly sessions will review the topics covered with a discussion of how participants have implemented the imparted knowledge to their daily lives. The sessions will be led by an experienced instructor who has conducted similar teaching sessions to the elderly.
Participants will be provided with hand-outs at each session, and there will be discussions to encourage them to practice what is being taught in their daily lives.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dementia
Keywords
Prevention of dementia, Mindful awareness program, Mild cognitive impairment, Mindfulness, Elderly, Cognitive decline
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
55 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Mindful Awareness Program
Arm Type
Experimental
Arm Description
18 sessions of mindful awareness program teaching the elderly mindful awareness practice techniques
Arm Title
Health Education Program
Arm Type
Active Comparator
Arm Description
18 sessions of health education program focusing on healthy living topics
Intervention Type
Behavioral
Intervention Name(s)
Mindful Awareness Program
Other Intervention Name(s)
MAP
Intervention Description
For Mindful Awareness Program, 40-minutes weekly sessions for 12 weeks, followed by 40-minutes monthly for 6 months. The mindful awareness practice techniques to be taught to the elderly include: (1) mindfulness of the senses practice; (2) the body scan practice; (3) walking meditation practice; (4) 'movement nature meant' practice; and (5) visuo-motor limb tasks
Intervention Type
Behavioral
Intervention Name(s)
Health Education Program
Other Intervention Name(s)
HEP
Intervention Description
For the Health Education Program, weekly sessions of 40 minutes for 12 weeks, followed by monthly sessions of 40 minutes for 6 months.
Week 1: Diabetes Mellitus Week 2: Hypertension Week 3: Home Safety Week 4: Medications Week 5: Diet Week 6: Depression Week 7: Dementia Week 8: Anxiety Week 9: Sleep Week 10: Exercise Week 11: Coping with bereavement Week 12: Social support
Primary Outcome Measure Information:
Title
Change from baseline Mini-Mental State Examination (MMSE) at 3 months and 9 months
Description
Mini-Mental State Examination (MMSE) is a brief 30-point questionnaire administered by health care professionals to screen for cognitive impairment. The score ranges from 0 to 30; the higher the score, the less impaired is the participant's cognitive function.
Time Frame
baseline, 3-months, 9-months
Title
Change from baseline Clinical Dementia Rating (CDR ) at 3 months and 9 months
Description
Clinical Dementia Rating (CDR ) is a 5-point scale used to characterize six domains of cognitive and functional performance applicable to Alzheimer disease and related dementias: Memory, Orientation, Judgment & Problem Solving, Community Affairs, Home & Hobbies, and Personal Care.
Time Frame
baseline, 3-months, 9-months
Title
Change from baseline Rey Auditory Verbal Learning Test (RAVLT) at 3 months and 9 months
Description
Rey Auditory Verbal Learning Test (RAVLT) evaluates declarative verbal learning and memory.
Time Frame
baseline, 3-months, 9-months
Title
Change from baseline Digit Span Task at 3 months and 9 months
Description
Digit Span Task, which consists of a Digit Span Forward (DSF) and a Digit Span Backward (DSB) task is used to assess attention and verbal working memory.
Time Frame
baseline, 3-months, 9-months
Title
Change from baseline Colour Trails Tests (CTT) at 3 months and 9 months
Description
Colour Trails Tests (CTT) 1 and 2 assesses sustained attention and sequencing.
Time Frame
baseline, 3-months, 9-months
Title
Change from baseline Block Design at 3 months and 9 months
Description
Block Design is a subtest that is administered as part of several of the Wechsler Intelligence tests, and it primarily measures visual-spatial and organizational processing abilities, as well as non-verbal problem-solving skills.
Time Frame
baseline, 3-months, 9-months
Title
Change from baseline Semantic Verbal Fluency (Animals) at 3 months and 9 months
Description
Semantic Verbal Fluency (Animals) taps lexical knowledge and semantic memory organization.
Time Frame
baseline, 3-months, 9-months
Title
Change from baseline fMRI scan at 3 months
Description
Functional Magnetic Resonance Imaging (fMRI) will be employed to examine changes in functional connectivity. Images will be acquired on a 3T Siemens scanner using a standard Siemens whole head coil. All subjects will undergo the task-free fMRI scan after being instructed only to remain awake with their eyes closed. White Matter Diffiusion Tractography Imaging (DTI) will be utilized to identify anatomical connections between functionally correlated regions . The MRI Brain Scan is non-invasive and does not involve the use of Contrast; duration of each scan is approximately one hour.
Time Frame
baseline, 3-months
Title
Change from baseline Biomarkers: blood sample at 3 months and 9 months
Description
5 ml of blood will be collected using plasma tubes with indomethacin (15uM final conc) and BHT (20ul of 2mM) will be added prior to freezing (-80 Degree Celsius) to preserve the sample and prevent artifacts (at baseline, 3 months, 9 months).
3 ml of blood will be collected using tubes with no coagulant (at baseline, 3 months and 9 months).
5 ml of blood will be collected using Tempus Blood RNA tubes and will be stored in a refrigerator at approximately 4 Degree Celsius (at baseline and 9 months).
Blood sample would be analysed for cytokine levels; chromosomal studies and terminal telomere restriction fragment length.
Time Frame
baseline, 3-months, 9-months
Title
Change from baseline Biomarkers: urine sample at 9 months
Description
15 ml sample of urine will be collected and frozen as quickly as possible. Urine sample would be analysed for oxidative biomarkers.
Time Frame
baseline, 9-months
Title
Change from baseline Biomarker - fecal sample at 3 months and 9 months
Description
A fecal sample will also be collected in a tube with RNALater and microbeads. These can be kept at 40C till processing. Fecal sample would be analysed for bacteria.
Time Frame
baseline,3 months, 9 months
Title
Change from baseline Biomarker - saliva sample at 3 months and 9 months
Description
Saliva will be collected in a test-tube by having participants continuously spit into a 50ml centrifuge tube for 5 minutes. Saliva sample would be analysed for salivary cortisol analysis, DNA extraction and sequencing for stress biomarkers (cytokines).
Time Frame
baseline,3 months, 9 months
Secondary Outcome Measure Information:
Title
Change from baseline Basic Health Screen at 3 months and 9 months
Description
the Blood pressure, Pulse rate, Height and Weight will be measured.
Time Frame
baseline, 3-months, 9-months
Title
Change from baseline Activities of daily Living (ADL) at 3 months and 9 months
Description
Activities of daily Living (ADL) is a questionnaire to screen for functional assessment.
Time Frame
baseline, 3-months, 9-months
Title
Change from baseline Instrumental Activities of Daily Living (IADL) at 3 months and 9 months
Description
Instrumental Activities of Daily Living (IADL) is a questionnaire to screen for functional assessment.
Time Frame
baseline, 3-months, 9-months
Title
Change from baseline Geriatric Depression Scale (GDS) at 3 months and 9 months
Description
Psychological well-being will be assessed using the Geriatric Depression Scale. Subjects with high scores will not be enrolled into the study and will be informed of the scores and advised to see a doctor at a polyclinic or their family physician with a referral letter prepared for this purpose.
Time Frame
baseline, 3-months, 9-months
Title
Change from baseline Geriatric Anxiety Inventory (GAI) at 3 months and 9 months
Description
Psychological well-being will be assessed using the Geriatric Anxiety Inventory (GAI). Subjects with high scores will not be enrolled into the study and will be informed of the scores and advised to see a doctor at a polyclinic or their family physician with a referral letter prepared for this purpose.
Time Frame
baseline, 3-months, 9-months
Other Pre-specified Outcome Measures:
Title
Demographic questionnaire
Time Frame
Baseline
10. Eligibility
Sex
All
Minimum Age & Unit of Time
60 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
an elderly person between the age of 60 and 85 living in the community and fulfill the operational criteria/definition of MCI:
At least one age-education adjusted neuropsychological test Z score < -1.5
Do not meet DSM-IV criteria for dementia syndrome
Memory / Cognitive complaint, preferably corroborated by a reliable informant
Intact Activities of Daily Living.
function independently
do not suffer from dementia,
able to travel on their own to the data collection site and participate in the MAP or HEP
Exclusion Criteria:
Those who do not meet the above inclusion criteria (ie. Do not have a MCI diagnosis),
Those with Dementia or Normal Ageing
Have a neurological condition (e.g., epilepsy, Parkinson's Disease),
Have a major psychiatric condition (e.g., major depressive disorder)
Suffer from a terminal illness (e.g., cancer).
Have significant visual or hearing impairment, or
Marked upper and lower limb motor difficulties, which may affect their ability to participate in the study.
Are in another interventional study at the same time
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rathi Mahendran, Ph.D
Organizational Affiliation
National University of Singapore
Official's Role
Principal Investigator
Facility Information:
Facility Name
Training and Research Academy
City
Singapore
ZIP/Postal Code
648886
Country
Singapore
12. IPD Sharing Statement
Citations:
PubMed Identifier
19751919
Citation
Roberts RO, Geda YE, Knopman DS, Boeve BF, Christianson TJ, Pankratz VS, Kullo IJ, Tangalos EG, Ivnik RJ, Petersen RC. Association of C-reactive protein with mild cognitive impairment. Alzheimers Dement. 2009 Sep;5(5):398-405. doi: 10.1016/j.jalz.2009.01.025.
Results Reference
background
PubMed Identifier
22210159
Citation
Moverare-Skrtic S, Johansson P, Mattsson N, Hansson O, Wallin A, Johansson JO, Zetterberg H, Blennow K, Svensson J. Leukocyte telomere length (LTL) is reduced in stable mild cognitive impairment but low LTL is not associated with conversion to Alzheimer's disease: a pilot study. Exp Gerontol. 2012 Feb;47(2):179-82. doi: 10.1016/j.exger.2011.12.005. Epub 2011 Dec 22.
Results Reference
background
PubMed Identifier
23827227
Citation
Huang L, Jia J, Liu R. Decreased serum levels of the angiogenic factors VEGF and TGF-beta1 in Alzheimer's disease and amnestic mild cognitive impairment. Neurosci Lett. 2013 Aug 29;550:60-3. doi: 10.1016/j.neulet.2013.06.031. Epub 2013 Jul 1.
Results Reference
background
PubMed Identifier
24571182
Citation
Gard T, Holzel BK, Lazar SW. The potential effects of meditation on age-related cognitive decline: a systematic review. Ann N Y Acad Sci. 2014 Jan;1307:89-103. doi: 10.1111/nyas.12348.
Results Reference
background
PubMed Identifier
19735247
Citation
Rapgay L, Bystrisky A. Classical mindfulness: an introduction to its theory and practice for clinical application. Ann N Y Acad Sci. 2009 Aug;1172:148-62. doi: 10.1111/j.1749-6632.2009.04405.x.
Results Reference
background
Citation
Mcbee, L. (2008) Mindfulness-based elder care. New York: Springer.
Results Reference
background
PubMed Identifier
24120430
Citation
Wells RE, Yeh GY, Kerr CE, Wolkin J, Davis RB, Tan Y, Spaeth R, Wall RB, Walsh J, Kaptchuk TJ, Press D, Phillips RS, Kong J. Meditation's impact on default mode network and hippocampus in mild cognitive impairment: a pilot study. Neurosci Lett. 2013 Nov 27;556:15-9. doi: 10.1016/j.neulet.2013.10.001. Epub 2013 Oct 10.
Results Reference
background
PubMed Identifier
12883106
Citation
Davidson RJ, Kabat-Zinn J, Schumacher J, Rosenkranz M, Muller D, Santorelli SF, Urbanowski F, Harrington A, Bonus K, Sheridan JF. Alterations in brain and immune function produced by mindfulness meditation. Psychosom Med. 2003 Jul-Aug;65(4):564-70. doi: 10.1097/01.psy.0000077505.67574.e3.
Results Reference
background
PubMed Identifier
22815014
Citation
Feng L, Chong MS, Lim WS, Ng TP. The Modified Mini-Mental State Examination test: normative data for Singapore Chinese older adults and its performance in detecting early cognitive impairment. Singapore Med J. 2012 Jul;53(7):458-62.
Results Reference
background
Citation
Schmidt, M. (1996). Rey auditory verbal learning test: A handbook. Los Angeles: Western Psychological Services.
Results Reference
background
PubMed Identifier
16523997
Citation
Conway AR, Kane MJ, Bunting MF, Hambrick DZ, Wilhelm O, Engle RW. Working memory span tasks: A methodological review and user's guide. Psychon Bull Rev. 2005 Oct;12(5):769-86. doi: 10.3758/bf03196772.
Results Reference
background
PubMed Identifier
10923062
Citation
Lee TM, Chan CC. Are trail making and color trails tests of equivalent constructs? J Clin Exp Neuropsychol. 2000 Aug;22(4):529-34. doi: 10.1076/1380-3395(200008)22:4;1-0;FT529.
Results Reference
background
Citation
Ardila, A., Ostrosky-Solís, F, & Bernal,B. (2006). Cognitive testing toward the future: The example of Semantic Verbal Fluency (ANIMALS), International Journal of Psychology, 41(5), 324-332
Results Reference
background
PubMed Identifier
8232972
Citation
Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993 Nov;43(11):2412-4. doi: 10.1212/wnl.43.11.2412-a. No abstract available.
Results Reference
background
PubMed Identifier
18596974
Citation
Dusek JA, Otu HH, Wohlhueter AL, Bhasin M, Zerbini LF, Joseph MG, Benson H, Libermann TA. Genomic counter-stress changes induced by the relaxation response. PLoS One. 2008 Jul 2;3(7):e2576. doi: 10.1371/journal.pone.0002576. Erratum In: PLoS One. 2017 Feb 21;12 (2):e0172845.
Results Reference
background
Learn more about this trial
Mindful Awareness Program for the Prevention of Dementia: A Randomized Controlled Trial
We'll reach out to this number within 24 hrs